JCP Business Summary

Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) is a Taiwan-based specialty and generic pharmaceutical manufacturer that generates revenue primarily through the production, import, and distribution of western medicines and raw pharmaceutical materials. The company’s business model is centered on a high-volume, diversified portfolio of over 200 drug types and functional foods, with primary revenue segments categorized by therapeutic application: central nervous system (CNS) agents, respiratory and cardiovascular treatments, gastrointestinal drugs, and endocrine system medications. Operating out of its PIC/S GMP-certified facility in New Taipei City, the company serves a broad network of medical centers, regional hospitals, and retail pharmacy chains like Watsons. Within the competitive landscape of the Taiwan pharmaceutical market, JCP competes directly with major local players such as Lotus Pharmaceutical (1795.TW), Nang Kuang Pharmaceutical (1752.TW), and SYN-Tech Chem & Pharm (1777.TW), positioning itself as a niche generic specialist with a dominant market presence in CNS-related therapeutic solutions. The company was founded in 1966 by Jung Fu Yang and has evolved into a family-controlled enterprise with deep industry pedigree. The current leadership is headed by Chairman and General Manager (CEO) Pai-Hsiung Huang, who has steered the company’s strategic direction since 1999 and maintains a significant controlling interest alongside his family members. The executive team and board of directors include key figures such as Director Liao Guo An, who provides oversight on the company’s long-term capital allocation and operational transparency. As of March 2026, the company remains publicly listed on the Taipei Exchange (TPEx), with notable institutional backing from entities such as Yao Sheng Electronic Co., Ltd. The leadership team recently demonstrated operational stability by securing board approval for the 2025 consolidated financial statements on March 10, 2026, reflecting a continued focus on maintaining a robust dividend payout ratio and sustainable growth in the Asian generic drug market.